Stocks Health care TLSI
NASDAQ · Health careTriSalus Life Sciences, Inc. (TLSI)
TriSalus Life Sciences, Inc. brought in $45.1M of revenue over the twelve months to June 30, 2026, up 25.2% from a year earlier. It posted a net loss of $28.2M. In fiscal 2025 capital spending exceeded operating cash flow by $18.9M. At June 30, 2026 it held $46.3M in cash against $33.1M of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 6, 2026.
Key facts about TriSalus Life Sciences, Inc.
- Net worth
- TriSalus Life Sciences, Inc. has a market value (market cap) of $175.5M at the latest share price, and shareholders' equity of $6.6M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $45.2M (+53.4% year on year), with a net loss of $39.2M. Over the 12 months to June 30, 2026: revenue $45.1M, net loss $28.2M.
- Cash flow
- In fiscal 2025 operations used $18M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 6, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- TriSalus Life Sciences, Inc.'s next report is expected around November 12, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
What TriSalus Life Sciences, Inc. does
TriSalus Life Sciences, Inc. is registered with the SEC under industry code SIC 3841 (Surgical & Medical Instruments & Apparatus). Its shares trade on NASDAQ under the ticker TLSI.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $45.2M | -$39.2M | -$1.84 | -$18.9M |
| 2024 | $29.4M | -$30M | -$1.31 | -$41.2M |
| 2023 | $18.5M | -$59.4M | -$6.77 | -$51.2M |
| 2022 | $12.4M | -$47.2M | -$161.55 | -$33M |
| 2021 | n/a | $4.8M | n/a | n/a |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where TLSI ranks in Health care
Latest SEC filings
What TriSalus Life Sciences, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 22, 2026Other event 8-K
- August 6, 2026Quarterly report 10-Q · period to June 30, 2026Revenue rose 1.7% to $11.4M versus the same quarter last year; diluted EPS -$0.16 versus -$0.27.
- August 6, 2026
- July 7, 2026Passive stake changed SCHEDULE 13G/A
- May 20, 2026Passive stake changed SCHEDULE 13G/A
- May 15, 2026Passive stake (5% or more) SCHEDULE 13G
- May 14, 2026
- May 12, 2026Quarterly report 10-Q · period to March 31, 2026Revenue fell 2.9% to $8.9M versus the same quarter last year; diluted EPS $0.03 versus -$0.39.
- May 12, 2026
- May 12, 2026Passive stake (5% or more) SCHEDULE 13G
Insider trades
What the people running TriSalus Life Sciences, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $4.1K worth of shares in the last 90 days and bought none on the open market.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| October 5, 2026 | Szela Mary TCEO and President, Director | Shares withheld for tax | 2,693 | $11.8K |
| October 5, 2026 | Stevens JenniferChief Regulatory Officer | Sold | 316 | $1.4K |
| October 5, 2026 | Marshak RichardChief Commercial Officer | Sold | 325 | $1.4K |
| October 5, 2026 | Cox Bryan F.Chief of Research | Sold | 296 | $1.3K |
| July 1, 2026 | Patience DavidChief Financial Officer | Shares withheld for tax | 14,650 | $65.3K |
| June 30, 2026 | Marshak RichardChief Commercial Officer | Received as pay | 561 | $2.2K |
| June 30, 2026 | Szela Mary TCEO and President, Director | Received as pay | 3,990 | $15.4K |
| June 29, 2026 | Marshall Richard HenryChief Medical Officer | Received as pay | 60,000 | - |
Who owns TLSI
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Frankenius Equity AB13D, may seek influence with 1 related filers | 20.5% | May 2, 2025 |
| First Light Asset Management, LLC13G, passive with 1 related filers | 10.74% | July 7, 2026 |
| Mats Wahlstrom13D, may seek influence with 2 related filers | 9% | December 19, 2024 |
| Utmost Group PLC13G, passive | 5.71% | May 12, 2026 |
| James J. Pallotta13G, passive | 5.2% | May 20, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 79 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| First Light Asset Management, LLC | 6,552,491 | +1,485,664 |
| BlackRock, Inc. | 2,659,218 | +1,159,671 |
| Nantahala Capital Management, LLC | 2,000,000 | -70,827 |
| Vanguard Capital Management LLC | 1,729,385 | +382,349 |
| Cerity Partners LLC | 1,603,538 | +816,266 |
| Geode Capital Management, LLC | 1,190,067 | +412,973 |
| Gilder Gagnon Howe & Co LLC | 850,081 | -38,434 |
| State Street Corp | 610,963 | +282,943 |
| White Pine Capital LLC | 547,577 | +183,922 |
| Kennedy Capital Management LLC | 476,261 | -8,981 |
| Morgan Stanley | 401,814 | +7,905 |
| Northern Trust Corp | 379,572 | +158,099 |
| Vanguard Portfolio Management LLC | 329,464 | +164,606 |
| Vanguard Fiduciary Trust Co | 320,956 | +102,604 |
| Lionhunter Capital Management, LLC | 300,275 | new |
| Perkins Capital Management Inc | 235,101 | +5,000 |
| UBS Group AG | 223,047 | +143,495 |
| Bank of America Corp | 205,342 | +3,623 |
| Royce & Associates LP | 200,060 | 0 |
| Corient Private Wealth LP | 147,152 | +56,152 |
Insiders
14 insiders reported holding 12,737,528 shares in total, about $36.3M at the last price.
| Holder | Shares |
|---|---|
| Frankenius Equity AB10% owner | 6,989,748 |
| Stansky Michael PDirector | 1,640,420399,698 held indirectly |
| Matlin David JDirector | 1,323,210 |
| Szela Mary TCEO and President, Director | 1,074,990 |
| Hicks Kerry RDirector | 542,790 |
| Patience DavidChief Financial Officer | 261,107 |
| Cox Bryan F.Chief of Research | 162,805 |
| Wahlstrom MatsDirector | 147,555 |
| Marshak RichardChief Commercial Officer | 127,994 |
| Stevens JenniferChief Regulatory Officer | 123,794 |
Questions about TLSI
What does TriSalus Life Sciences, Inc. do?
TriSalus Life Sciences, Inc. is a company in the Health care sector, listed on NASDAQ as TLSI. Its shares trade on NASDAQ under the ticker TLSI.
What is TriSalus Life Sciences, Inc.'s net worth?
TriSalus Life Sciences, Inc. has a market value (market cap) of $175.5M at the latest share price, and shareholders' equity of $6.6M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is TriSalus Life Sciences, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $28.2M on revenue of $45.1M.
How much revenue does TriSalus Life Sciences, Inc. make?
Over the twelve months to June 30, 2026 TriSalus Life Sciences, Inc. reported revenue of $45.1M. That is 25.2% more than a year earlier.
When did TriSalus Life Sciences, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 6, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the insider trade from October 7, 2026.
When is TriSalus Life Sciences, Inc.'s next earnings report?
TriSalus Life Sciences, Inc.'s next report is expected around November 12, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare TLSI with
Follow TLSI
Get an email when TriSalus Life Sciences, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values TriSalus Life Sciences, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.